Chronic Pain
Conditions
Brief summary
This randomized Stage 1 pilot trial tests the feasibility of a community health worker (CHW) delivered chronic pain self-management intervention for older adults ("STEP-UP"; Support, Training, and Education for Pain Self-Management - Using Podcasts) in a primary care setting. A total of 40 participants aged 50+ with high-impact chronic pain will be randomized to intervention or control groups. The STEP-UP intervention will feature an educational podcast series teaching core pain self-management skills. Podcasts will be supplemented by sessions with a Community Health Worker taking place at designated times over a 7-week period. The Community Health Worker will guide participants in a modified Patient Priorities of Care approach to help them identify their values and priorities and develop goals that reflect these.
Interventions
The STEP-UP chronic pain self-management intervention (Support, Training, and Education for Pain Self-Management - Using Podcasts) will feature an educational podcast series teaching core pain self-management skills. Podcasts will be supplemented by sessions with a Community Health Worker taking place at designated times over a 7-week period. The Community Health Worker will guide participants in a modified Patient Priorities of Care (PPC) approach to help them identify their values and priorities and develop goals that reflect these.
Sponsors
Study design
Eligibility
Inclusion criteria
* Age \> 50 years * Have a mobile or landline phone * Report high-impact chronic musculoskeletal pain (defined as pain in muscles or joints for \> 3 months "most days" or "every day" on a scale of never, some days, most days, or every day) AND their pain limited life or work activities over the past 3 months "most days" or "every day" * Have not participated in another chronic pain self-management intervention in the last 5 years. * Able to converse comfortably in English
Exclusion criteria
* Serious acute illness or hospitalization in the last month; * Planned major surgery in the next three months that would interfere with program participation (e.g., knee or hip replacement) * Severe cognitive impairment or other severe physical or psychiatric disorder judged by the study team to pose a significant barrier to participation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Pain Interference 6-item Subscale From PROMIS-43 Adult Profile | Baseline, 8 weeks from baseline | Items ask how much pain in the last 7 days has interfered with daily activities such as household chores and social activities (1=not at all to 5=very much); raw total scale scores range from 6 (low interference) to 30 (high interference). Scores are converted to a standardized T-score metric, with a mean of 50 and a standard deviation of 10 in a referent population. A higher score means more of the concept being measured. Change scores are calculated as \[8 week score\] - \[baseline score\]; therefore, a greater negative value means a greater reduction in pain interference. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Global Impression of Change in Pain | 8 weeks from baseline | How participant thinks their pain has changed from baseline (much worse (-3) to much better(+3)). |
| Global Impression of Change in Functioning | 8 weeks from baseline | How participant thinks their functioning has changed from baseline (much worse (-3) to much better(+3)). |
| Engagement as Measured by Number of Sessions Completed | 8 weeks from baseline | Number of sessions out of 6 completed 8 weeks from baseline |
| Participant Satisfaction | 8 weeks from baseline | Items ask about overall satisfaction with the program, e.g., whether participation increased understanding of pain management (1= Strongly Disagree to 5= Strongly Agree). A higher score indicates higher patient satisfaction. |
Countries
United States
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 59.85 years STANDARD_DEVIATION 5.81 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 19 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 13 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 13 Participants |
| Sex: Female, Male Female | 33 Participants |
| Sex: Female, Male Male | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 20 | 0 / 20 |
| other Total, other adverse events | 1 / 20 | 0 / 20 |
| serious Total, serious adverse events | 2 / 20 | 0 / 20 |